Ultragenyx Pharmaceutical Inc. / Fundamentals
Income statement
- Net revenue
€525.68M - Cost of goods sold
€84.60M - Gross profit
€441.08M - SG&A expenses
€290.59M - R&D expenses
€585.65M - EBITDA
-€375.06M - D&A
€30.54M - EBIT
-€435.16M - Interest expenses
€51.36M - EBT
-€456.96M - Tax expenses
€2.19M - Net income
-€459.15M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€69.65M - Changes in working capital
€46.16M - Operating cash flow
-€362.92M - Capex
€5.22M - Other investing cash flow
-€14.14M - Net investing cash flow
€15.76M - Total cash dividends paid
€0.00 - Issuance of common stock
€68.79M - Debt repayment
€0.00 - Other financing cash flow
€15.78M - Net financing cash flow
€84.57M - Foreign exchange effects
€2.73M - Net change in cash
-€256.93M - Cash at end of period
€162.53M - Free cash flow
-€357.71M
Balance sheet
- Cash and cash equivalents
€159.68M - Cash and short-term investments
€427.86M - Total receivables
€108.01M - Inventory
€40.06M - Other current assets
€44.20M - Total current assets
€620.13M - Property, plant & equipment
€220.35M - Goodwill
€38.26M - Intangible assets
€150.54M - Long-term investments
€47.18M - Other non-current assets
€48.95M - Total non-current assets
€505.28M - Total assets
€1.13B - Accounts payable
€29.50M - Short-term debt
€65.16M - Other current liabilities
€157.98M - Total current liabilities
€252.64M - Long-term debt
€695.51M - Deferred tax liabilities
€25.90M - Other non-current liabilities
€14.99M - Total non-current liabilities
€736.40M - Total liabilities
€989.04M - Common stock
€82.71K - Retained earnings
-€3.64B - Other equity
€6.65M - Total equity
€136.37M - Total liabilities and shareholders' equity
€1.13B
Company information
- Market capitalization
€2.94B - Employees
1.3K - Enterprise Value
€3.46B
Company ratios
- Gross margin
-
83.9% Much better than peer group: -50,862,001,554,175.9% - EBITDA margin
-
-71.3% Much better than peer group: -279,673,371,896,245.1% - EBIT margin
-
-82.8% Much better than peer group: -282,284,238,122,198.2% - EBT margin
-
-86.9% Much better than peer group: -281,949,257,705,352.1% - Net margin
-
-87.3% Much better than peer group: -281,949,257,705,394.6% - ROE
-
-336.7% Much worse than peer group: -35.2% - ROA
-
-40.8% Even with peer group: -36.6% - Asset turnover
-
46.7% Much better than peer group: 19.7% - FCF margin
-
-70.0% Much better than peer group: -234,925,450,308,608.9% - FCF yield
-12.5% - Efficiency ratio
171.3% - Net sales per employee
-
€406.25K - Net income per employee
-
-€354.83K